Key result
Modern era heart transplants linked to ~15% higher absolute 10-year survival versus earlier cohorts.
Why the study?
Donor and recipient characteristics and medical management of heart transplantation patients have changed markedly over past decades, and their impact on long-term clinical outcome was studied.
Does modern medical management improve long-term survival in heart transplant recipients despite increasing donor age compared to historical management?
Cohort (n=580)
No
Does modern medical management improve long-term survival in heart transplant recipients despite increasing donor age compared to historical management?
Long-term survival after heart transplantation has improved significantly over the last decade despite the use of older donors, likely due to advances in medical management such as tacrolimus and early statin therapy.
Answers are grounded in this paper and cite their sources.
May improve long-term heart transplant survival with modern regimens despite older donors; extends observational data but leaves causal effects open.
Over the past decades donor and recipient characteristics and medical management of heart transplantation (HT) patients have changed markedly. We studied the impact of these changes on long-term clinical outcome. Data of all consecutive HT recipients in our center have been collected prospectively. Cohort A (n = 353) was defined as the adult pts transplanted between 1984 and 1999 and was compared with cohort B (n = 227) transplanted between 2000 and 2013. Compared with cohort A, recipients in cohort B had older donors (mean age 29 vs. 43 years, donors aged >50 year: 2% vs. 33%, respectively). Survival at 1 and 10 years in cohort A vs. B was 89% vs. 86% and 53% vs. 68%, respectively (P = 0.02). Cohort B pts were treated more often with tacrolimus-based immunosuppression (77% vs. 22%; P = <0.0001) and early statins post-HT (88% vs. 18%; P = 0.0001), while renal function was better conserved at 5 and 10 years (P = 0.001 and 0.02). Multivariate analysis showed significant reduction in 10-year mortality with tacrolimus-based immunosuppression (HR 0.27 and 95% CI 0.17-0.42), hypertension post-HT (HR 0.5, 95% CI 0.36-0.72), and revascularization (HR 0.28, 95% CI 0.15-0.52). In spite of the use of much older donors, the long-term outcome after HT has improved considerably in the last decade, probably due to the introduction of newer treatment modalities.
No takes yet. Share an insight, caveat, or question.
Zijlstra et al. (2014) conducted a cohort in Heart transplantation (n=580). Transplantation between 2000 and 2013 (Cohort B) vs. Transplantation between 1984 and 1999 (Cohort A) was evaluated on 10-year survival (p=0.02). Heart transplant recipients transplanted between 2000 and 2013 had higher 10-year survival compared to those transplanted between 1984 and 1999.
Synapse has enriched 10 related papers. Consider them for comparative context: